文献速递颈动脉与弓上血管

冠状动脉旁路移植合并颈动脉粥样硬化性疾病患者治疗策略的系统综述与荟萃分析

Systematic review and meta-analysis of the treatment strategies for coronary artery bypass graft patients with concomitant carotid artery atherosclerotic disease.
PubMed 文献 · J Vasc Surg · 2023-05-29

该系统综述与网络荟萃分析比较了冠状动脉旁路移植(CABG)合并颈动脉粥样硬化性疾病患者接受额外颈动脉干预策略的安全性与有效性,纳入2项随机对照试验和23项观察性研究、共32473例患者。结果显示,与单纯CABG相比,没有任何策略在所有围手术期结局上显示出显著优势;颈动脉内膜切除术(CEA)后分期CABG的围手术期卒中/短暂性脑缺血发作(TIA)率最低,但围手术期死亡率和心肌梗死率最高。

要点

  • CEA后分期CABG的围手术期卒中/TIA率最低,但围手术期死亡率与心肌梗死率最高。
  • 与单纯CABG相比,没有任何策略在所有围手术期结局上显示出显著优势。
  • 作者强调应个体化选择策略并确定颈动脉干预的恰当适应证。

核心结论

  • CEA后分期CABG与较低的围手术期卒中/TIA率相关,代价是更高的死亡率和心肌梗死率。
  • 与单纯CABG相比,没有任何策略在所有围手术期结局上显示出显著优势,作者指出个体化方案及确定颈动脉干预恰当适应证的重要性。

研究设计与样本

  • 网络荟萃分析,检索MEDLINE和EMBASE截至2022年2月的文献,纳入2项随机对照试验和23项观察性研究,共32473例患者。
  • 患者分组:联合CEA与CABG(n=20204)、CEA后分期CABG(n=6882)、CABG后分期CEA(n=340)、无论时机与顺序的颈动脉支架置入(CAS)与CABG(n=1224)、单纯CABG(n=3823)。

主要发现

  • 与单纯CABG相比,没有任何策略在所有围手术期结局上显示出显著优势。
  • CEA后分期CABG的围手术期卒中/TIA率最低,显著低于CAS与CABG(OR 0.52,95%CI 0.36-0.76)以及CABG后分期CEA(OR 0.41,95%CI 0.23-0.74)。
  • CEA后分期CABG的围手术期死亡率最高(与CAS和CABG相比OR 2.50,95%CI 1.67-3.85)。
  • CEA后分期CABG的心肌梗死率最高:与CAS和CABG相比OR 3.70(95%CI 1.16-12.5),与联合CEA和CABG相比OR 2.50(95%CI 1.35-4.55)。

关键数值与推荐

  • CEA后分期CABG与CAS和CABG相比,围手术期卒中/TIA的OR 0.52(95%CI 0.36-0.76)。
  • CEA后分期CABG与CABG后分期CEA相比,围手术期卒中/TIA的OR 0.41(95%CI 0.23-0.74)。
  • CEA后分期CABG与CAS和CABG相比,围手术期死亡的OR 2.50(95%CI 1.67-3.85)。
  • CEA后分期CABG与CAS和CABG相比心肌梗死的OR 3.70(95%CI 1.16-12.5),与联合CEA和CABG相比OR 2.50(95%CI 1.35-4.55)。

临床怎么用

  • 作者认为,CEA后分期CABG与低围手术期卒中/TIA率相关,但以更高的死亡率和心肌梗死率为代价。
  • 作者指出没有任何策略在所有围手术期结局上优于单纯CABG,强调个体化方案并确定颈动脉干预恰当适应证的重要性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Stroke is one of the devastating complications after coronary artery bypass graft (CABG). Underlying carotid artery atherosclerotic disease is reported to be an independent risk factor. The optimal treatment strategy for these patients remains under debate. METHODS: We aimed to perform a network meta-analysis to evaluate the safety and efficacy of additional carotid interventions for patients with concomitant carotid artery atherosclerotic disease who require CABG by comparing perioperative adverse event rates. All articles through February 2022 were searched using MEDLINE and EMBASE to identify studies that investigated outcomes of CABG only as well as additional staged vs combined carotid interventions by both carotid endarterectomy (CEA) and carotid artery stenting (CAS). RESULTS: Two randomized controlled trials and 23 observational studies were included, yielding a total of 32,473 patients who underwent combined CEA and CABG (n = 20,204), CEA and staged CABG (n = 6882), CABG and staged CEA (n = 340), CAS and CABG regardless of timing and sequences (n = 1224), and CABG only (n = 3823). No strategy showed a significant advantage over CABG only in all perioperative outcomes. CEA and staged CABG was associated with the lowest perioperative stroke/transient ischemic attack (TIA) rate, significantly lower compared with CAS and CABG (odds ratio [OR], 0.52; 95% confidence interval [CI], 0.36-0.76) as well as CABG and staged CEA (OR, 0.41; 95% CI, 0.23-0.74), but was also associated with the highest perioperative mortality (OR, 2.50; 95% CI, 1.67-3.85, vs CAS and CABG) and myocardial infarction rate (OR, 3.70 [95% CI, 1.16-12.5] and OR, 2.50 [95% CI, 1.35-4.55] vs CAS and CABG, vs combined CEA and CABG, respectively). CONCLUSIONS: CEA and staged CABG are associated with low perioperative stroke/transient ischemic attack rates with a tradeoff of higher mortality and myocardial infarction rate. No strategy showed a significant advantage over the CABG-only strategy in all perioperative outcomes, outlining the importance of a tailored approach and determining proper indications for carotid intervention in these patients.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Tsukagoshi J, Yokoyama Y, Fujisaki T, et al. Systematic review and meta-analysis of the treatment strategies for coronary artery bypass graft patients with concomitant carotid artery atherosclerotic disease. J Vasc Surg. 2023. PMID: 37257673. doi:10.1016/j.jvs.2023.04.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。